First-Line Treatment with Tiotropium/Olodaterol Improves Physical Activity in Patients with Treatment-Naïve Chronic Obstructive Pulmonary Disease

First-Line Treatment with Tiotropium/Olodaterol Improves Physical Activity in Patients with Treatment-Naïve Chronic Obstructive Pulmonary Disease

Koichiro Takahashi,1 Masaru Uchida,2 Go Kato,3 Ayako Takamori,4 Takashi Kinoshita,5 Makoto Yoshida,6 Ryo Tajiri,4 Keisuke Kojima,7 Hiroshi Inoue,8 Hiromi Kobayashi,9 Hironori Sadamatsu,1 Hiroki Tashiro,1 Masahide Tanaka,1 Shinichiro Hayashi,10 Atsushi Kawaguchi,4,11 Shinya Kimura,1 Naoko Sueoka-Arag...

Full description

Bibliographic Details
Main Authors:	Takahashi K, Uchida M, Kato G, Takamori A, Kinoshita T, Yoshida M, Tajiri R, Kojima K, Inoue H, Kobayashi H, Sadamatsu H, Tashiro H, Tanaka M, Hayashi S, Kawaguchi A, Kimura S, Sueoka-Aragane N, Kawayama T
Format:	Article
Language:	English
Published:	Dove Medical Press 2020-09-01
Series:	International Journal of COPD
Subjects:	chronic obstructive pulmonary disease physical activity long-acting muscarinic antagonist long-acting beta 2 agonist
Online Access:	https://www.dovepress.com/first-line-treatment-with-tiotropiumolodaterol-improves-physical-activ-peer-reviewed-article-COPD

Similar Items

Evaluation of rescue medication use and medication adherence receiving umeclidinium/vilanterol versus tiotropium bromide/olodaterol
by: Moretz C, et al.
Published: (2019-09-01)

Barriers to achieving asthma control in adults: evidence for the role of tiotropium in current management strategies
by: Jenkins C
Published: (2019-03-01)

Direct Switch from Tiotropium to Indacaterol/Glycopyrronium in Chronic Obstructive Pulmonary Disease Patients in Korea
by: Sang Haak Lee, et al.
Published: (2021-04-01)

Frequency of Tiotropium Bromide Use and Clinical Features of Patients with Severe Asthma in a Real-Life Setting: Data from the Severe Asthma Network in Italy (SANI) Registry
by: Puggioni F, et al.
Published: (2020-11-01)

A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 µg compared with tiotropium 18 µg in patients with COPD
by: Feldman G, et al.
Published: (2016-04-01)

Improvement in 24-hour bronchodilation and symptom control with aclidinium bromide versus tiotropium and placebo in symptomatic patients with COPD: post hoc analysis of a Phase IIIb study
by: Beier J, et al.
Published: (2017-06-01)

The effect of glycopyrronium and indacaterol, as monotherapy and in combination, on the methacholine dose-response curve of mild asthmatics: a randomized three-way crossover study
by: Christianne M. Blais, et al.
Published: (2017-08-01)

Cost-effectiveness of umeclidinium compared with tiotropium and glycopyrronium as monotherapy for chronic obstructive pulmonary disease: a UK perspective
by: Dhvani Shah, et al.
Published: (2018-05-01)

Critical Error Frequency and the Impact of Training with Inhalers Commonly used for Maintenance Treatment in Chronic Obstructive Pulmonary Disease
by: Collier DJ, et al.
Published: (2020-06-01)

Combinations of long acting β2 agonists to tiotropium: A randomized, double-blind, placebo-controlled, active-drug controlled, parallel design academic clinical trial in moderate COPD male patients
by: Mohammed Imran, et al.
Published: (2015-01-01)

Interactions between glycopyrronium and indacaterol on cholinergic neurotransmission and contractile response in bovine trachealis
by: Michele Baroffio, et al.
Published: (2017-07-01)

Treatment after a COPD exacerbation
by: Robbins RA
Published: (2013-07-01)

Tiotropium in chronic obstructive pulmonary disease – a review of clinical development
by: Antonio Anzueto, et al.
Published: (2020-07-01)

Inhaled glycopyrrolate for the treatment of chronic obstructive pulmonary disease
by: Tashkin DP, et al.
Published: (2018-06-01)

Effects of inhaler therapy on mortality in patients with tuberculous destroyed lung and airflow limitation
by: Kim HC, et al.
Published: (2019-03-01)

COST-MINIMIZATION OF VILANTEROL / UMECLIDINIUM VERSUS OLODATEROL / TIOTROPIUM IN THE BASIC THERAPY OF SEVERE AND VERY SEVERE COPD
by: E. G. Kosolapov, et al.
Published: (2017-08-01)

Relationship of inhaled long-acting bronchodilators with cardiovascular outcomes among patients with stable COPD: a meta-analysis and systematic review of 43 randomized trials
by: Li CX, et al.
Published: (2019-04-01)

A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy
by: Mapel D, et al.
Published: (2017-06-01)

Predicting treatable traits for long-acting bronchodilators in patients with stable COPD
by: Kang J, et al.
Published: (2017-12-01)

Maintenance therapy in COPD: time to phase out ICS and switch to the new LAMA/LABA inhalers?
by: Tariq SM, et al.
Published: (2017-06-01)

Revefenacin: A Once-Daily, Long-Acting Bronchodilator For Nebulized Treatment Of COPD
by: Donohue JF, et al.
Published: (2019-12-01)

Effect of Tiotropium Soft Mist Inhalers on Dynamic Changes in Lung Mechanics of Patients with Chronic Obstructive Pulmonary Disease Receiving Mechanical Ventilation: A Prospective Pilot Study
by: Pin-Kuei Fu, et al.
Published: (2021-12-01)

Determinants of response to inhaled extrafine triple therapy in asthma: analyses of TRIMARAN and TRIGGER
by: Dave Singh, et al.
Published: (2020-10-01)

Physical Functioning in Patients with Chronic Obstructive Pulmonary Disease Treated with Tiotropium/Olodaterol Respimat in Routine Clinical Practice in Italy
by: Mauro Carone, et al.
Published: (2020-06-01)

Effectiveness and Tolerability of LABA/LAMA Fixed-Dose Combinations Aclidinium/Formoterol, Glycopyrronium/Indacaterol and Umeclidinium/Vilanterol in the Treatment of COPD in Daily Practice – Results of the Non-Interventional DETECT Study
by: Plate T, et al.
Published: (2020-06-01)

Dual bronchodilators in chronic obstructive pulmonary disease: Evidence from randomized controlled trials and real-world studies
by: Antonio Anzueto, et al.
Published: (2020-11-01)

Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis
by: James F. Donohue, et al.
Published: (2020-05-01)

Long-Term Safety and Efficacy of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD
by: Ichinose M, et al.
Published: (2019-12-01)

Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD: A Subgroup Analysis of the KRONOS Study
by: Ichinose M, et al.
Published: (2019-12-01)

Long-Acting Bronchodilator Use in Chronic Obstructive Pulmonary Disease in Primary Care in New Zealand: A Retrospective Study of Treatment Patterns and Evolution Using the HealthStat Database
by: Milea D, et al.
Published: (2021-04-01)

Striving for optimal bronchodilation: focus on olodaterol
by: Incorvaia C, et al.
Published: (2016-03-01)

Tiotropium as an Add-on Treatment Option for Severe Uncontrolled Asthma in Preschool Patients
by: Zielen S, et al.
Published: (2021-01-01)

Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials
by: Gary T. Ferguson, et al.
Published: (2020-05-01)

Efficacy and safety of four doses of glycopyrrolate/formoterol fumarate delivered via a metered dose inhaler compared with the monocomponents in patients with moderate-to-severe COPD
by: Reisner C, et al.
Published: (2018-06-01)

Experience of using double bronchodilation therapy in patients with COPD
by: I. V. Demko, et al.
Published: (2021-01-01)

Discovering the Relative Efficacy of Inhaled Medications for Chronic Obstructive Pulmonary Disease: Multiple Treatment Comparisons
by: Ying Zhu, et al.
Published: (2017-03-01)

Rescue medication use as a patient-reported outcome in COPD: a systematic review and regression analysis
by: Yogesh Suresh Punekar, et al.
Published: (2017-05-01)

A phase IIb randomized, chronic-dosing, incomplete block, cross-over study of glycopyrronium, delivered via metered dose inhaler, compared with a placebo and an active control in patients with moderate-to-severe COPD
by: Edward M. Kerwin, et al.
Published: (2018-03-01)

Impact and prevention of severe exacerbations of COPD: a review of the evidence
by: Halpin DMG, et al.
Published: (2017-10-01)

Olodaterol exerts anti-inflammatory effects on COPD airway epithelial cells
by: Nan Yang, et al.
Published: (2021-02-01)